Plasma phospholipid transfer protein-mediated reactions are impaired by hypochlorite-modification of high density lipoprotein

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 2, 2003, Pages 192-202

  Pussinen, Pirkko J ^a   Metso, Jari ^b   Keva, Ritva ^b   Hirschmugl, Birgit ^c   Sattler, Wolfgang ^c   Jauhiainen, Matti ^b   Malle, Ernst ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

apoA I; HDL conversion; Oxidized modified HDL; Phospholipid; PLTP; Pre HDL

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HYPOCHLORITE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; CARRIER PROTEIN; HIGH DENSITY LIPOPROTEIN 3; HYPOCHLOROUS ACID; MEMBRANE PROTEIN;

ARTICLE; IMMUNOREACTIVITY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN SECRETION; BLOOD; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION;

APOLIPOPROTEIN A-I; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOCHLOROUS ACID; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL3; MEMBRANE PROTEINS; OXIDATION-REDUCTION; PHOSPHOLIPID TRANSFER PROTEINS; PROTEIN BINDING; TRIGLYCERIDES;

EID: 0037290731     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00130-9     Document Type: Article

References (50)

1. von Eckardstein A., Nofer J.R., Assman G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21:2001;13-27.
2. Castro G.R., Fielding C.J. Early incorporation of cell-derived cholesterol into preβ-migrating high density lipoprotein. Biochemistry. 27:1988;25-29.
3. Bodzioch M., Orsó E., Klucken J., Langmann T., Böttcher A., Diedrich W., Drobnik W., Barlage S., Büchler C., Porsch-Özcürümez M., Kaminski W.E., Hahmann H.W., Oette K., Rothe G., Aslanidis C., Lackner K.J., Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:1999;347-351.
4. Qin S., Kawano K., Bruce C., Lin M., Bisgaier C., Tall A.R., Jiang W. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J. Lipid Res. 41:2000;269-276.
5. Tall A.R., Krumholz S., Olivecrona T., Deckelbaum R.J. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J. Lipid Res. 26:1985;842-851.
6. Huuskonen J., Olkkonen V.M., Jauhiainen M., Metso J., Somerharju P., Ehnholm C. Acyl chain and headgroup specificity of human plasma phospholipid transfer protein. Biochim. Biophys. Acta. 1303:1996;207-214.
7. Desrumaux C., Athias A., Masson D., Gambert P., Lallemant C., Lagrost L. Influence of the electrostatic charge of lipoprotein particles on the activity of the human plasma phospholipid transfer protein. J. Lipid Res. 39:1998;131-142.
8. Pussinen P., Jauhiainen M., Ehnholm C. The apoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. J. Lipid Res. 38:1997;12-21.
9. Cheung M.C., Wolfbauer G., Albers J.J. Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim. Biophys. Acta. 1303:1996;103-110.
10. Huuskonen J., Olkkonen V.M., Ehnholm C., Metso J., Julkunen I., Jauhiainen M. Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion. Biochemistry. 39:2000;16092-16098.
11. Bonnefont-Rousselot D., Therond P., Beaudeux J.L., Peynet J., Legrand A., Delattre J. High density lipoprotein (HDL) and the oxidative hypothesis of atherosclerosis. Clin. Chem. Lab. Med. 37:1999;939-948.
12. Kettle A.J., Winterbourn C.C. Myeloperoxidase: a key regulator of neutrophil oxidant production. Redox Rep. 3:1997;3-15.
13. Hazell L.J., Arnold L., Flowers D., Waeg G., Malle E., Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97:1996;1535-1544.
14. 2-halide system in human atherosclerotic lesions: co-localization of myeloperoxidase and hypochlorite-modified proteins. Eur. J. Biochem. 267:2000;4495-4503.
15. G. Marsche, A. Hammer, O. Oskolkova, K.F. Kozarsky, W. Sattler, E. Malle, Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport, J. Biol. Chem., 17 June 2002 as 10.1074/jbc.M200503200.
16. Panzenboeck U., Raitmayer S., Reicher H., Lindner H., Glatter O., Malle E., Sattler W. Effect of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoprotein. J. Biol. Chem. 272:1997;29711-29720.
17. Hazell L.J., Stocker R. Oxidation of low density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high uptake form for macrophages. Biochem. J. 290:1993;165-172.
18. Kopprasch S., Leonhardt W., Pietzsch J., Kühne H. Hypochlorite-modified low density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion and adhesion to endothelial cells. Atherosclerosis. 136:1998;315-324.
19. Opper C., Schüssler G., Sattler W., Malle E. Effects of hypochlorite-modified low density lipoproteins and high density lipoproteins on platelet function. Platelets. 9:1998;339-341.
20. 2+-ATPase activity of human platelets. Cell Calcium. 26:1999;281-287.
21. Woenckhaus C., Kaufmann A., Bussfeld D., Gemsa D., Sprenger H., Gröne H.J. Hypochlorite-modified LDL: chemotactic potential and chemokine induction in human monocytes. Clin. Immunol. Immunopathol. 86:1998;27-33.
22. Nuszkowski A., Gräbner R., Marsche G., Unbehaun A., Malle E., Heller R. Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric oxide synthase. J. Biol. Chem. 276:2001;14212-14221.
23. Bergt C., Reicher H., Malle E., Sattler W. Hypochlorite-modification of high density lipoprotein: effects on cholesterol efflux from J774 macrophages. FEBS Lett. 452:1999;295-300.
24. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
25. Rye K.A., Jauhiainen M., Barter P.J., Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J. Lipid Res. 39:1998;613-622.
26. Huuskonen J., Ekström M., Tahvanainen E., Vainio A., Metso J., Pussinen P., Ehnholm C., Olkkonen V., Jauhiainen M. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid activity. Atherosclerosis. 151:2000;451-461.
27. Groener J.E.M., Pelton R.W., Kostner G.M. Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. Clin. Chem. 32:1986;283-286.
28. Jauhiainen M., Dolphin P.J. Human plasma lecithin-cholesterol acyltransferase: an elucidation of catalytic mechanism. J. Biol. Chem. 261:1986;7032-7043.
29. 14C ]-phosphatidylcholine between liposomes Biochim. Biophys. Acta. 712:1982;444-452.
30. van Haperen R., van Tol A., Vermeulen P., Jauhiainen M., van Gent T., van den Berg P., Ehnholm S., Grosveld F., van der Kamp A., de Crom R. Human plasma phospholipid transfer protein increases the anti-atherogenic potential of high density lipoprotein in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 20:2000;1082-1088.
31. 3 in vitro and its effect on PLTP-mediated phospholipid transfer. Biochim. Biophys. Acta. 1391:1998;181-192.
32. Kleinherenbrink-Stins M.F., Schouten D., van der Boom J., Brouwer A., Knook D.L., van Berkel T.J. Nitrosylated high density lipoprotein is recognized by a scavenger receptor in rat liver. J. Lipid Res. 30:1989;511-520.
33. Miyazaki A., Sakai M., Yamaguchi E., Sakamoto Y., Shichiri M., Horiuchi S. Two independent macrophage receptors for acetylated high density lipoprotein. Biochim. Biophys. Acta. 1170:1993;143-150.
34. Musanti R., Ghiselli G. Interaction of oxidized HDLs with J774-A1 macrophages causes intracellular accumulation of unesterified cholesterol. Arterioscler. Thromb. 13:1993;1334-1345.
35. Marsche G., Levak-Frank S., Quehenberger O., Heller R., Sattler W., Malle E. Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J. 15:2001;1095-1097.
36. Maziere J.C., Myara I., Salmon S., Auclair M., Haigle J., Santus R., Maziere C. Copper- and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin-cholesterol acyltransferase activation. Atherosclerosis. 104:1993;213-219.
37. McCall M.R., Carr A.C., Forte T.M., Frei B. LDL modified by hypochlorous acid is a potent inhibitor of lecithin-cholesterol acyltransferase activity. Arterioscler. Thromb. Vasc. Biol. 21:2001;1040-1045.
38. Masson D., Athias A., Lagrost L. Evidence for electronegativity of plasma high density lipoprotein subclass 3 as one major determinant of human cholesteryl ester transfer protein activity. J. Lipid Res. 37:1996;1579-1590.
39. Davit-Spraul A., Therond P., Leroy A., Palmade-Rieunier F., Rousset C., Moatti N., Legrand A. Inhibition of lecithin-cholesterol acyltransferase by phosphatidylcholine hydroperoxides. FEBS Lett. 447:1999;106-110.
40. Huuskonen J., Wohlfahrt G., Jauhiainen M., Ehnholm C., Teleman O., Olkkonen V.M. Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis. J. Lipid Res. 40:1999;1123-1130.
41. Pussinen P.J., Jauhiainen M., Metso J., Pyle L.E., Marcel Y.L., Fidge N.H., Ehnholm C. Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I. J. Lipid Res. 39:1998;152-161.
42. Bergt C., Oettl K., Keller W., Andreae F., Leis H.J., Malle E., Sattler W. Reagent or myeloperoxidase-generated hypochlorite affects discrete regions in lipid-free and -associated human apolipoprotein A-I. Biochem. J. 346:2000;345-354.
43. Roberts L.M., Ray M.J., Shih T.W., Hayden E., Reader M.M., Brouillette C.G. Structural analysis of apolipoprotein A-I: limited proteolysis of methionine-reduced and -oxidized lipid-free and -bound human apoA-I. Biochemistry. 36:1997;7615-7624.
44. Fielding P.E., Kawano M., Catapano A.L., Zoppo A., Marcovina S., Fielding C.J. Unique epitope of apolipoprotein A-I expressed in preβ-1 high density lipoprotein and its role in the catalyzed efflux of cellular cholesterol. Biochemistry. 33:1994;6981-6985.
45. -), a product of the myeloperoxidase system, degrades articular cartilage proteoglycan aggregate. Free Radic. Biol. Med. 10:1991;101-109.
46. Bergt C., Marsche G., Panzenboeck U., Heinecke J.W., Malle E., Sattler W. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to oxidatively damage apolipoprotein A-I. Eur. J. Biochem. 268:2001;3523-3531.
47. Zhang R., Brennan M.L., Fu X., Aviles R.J., Pearce G.L., Penn M.S., Topol E.J., Sprecher D.L., Hazen S.L. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 286:2001;2136-2142.
48. Malle E., Woenckhaus C., Waeg G., Esterbauer H., Gröne E.F., Gröne H.J. Immunological evidence for hypochlorite-modified proteins in human kidney. Am. J. Pathol. 150:1997;603-615.
49. Scheuer H., Gwinner W., Hohbach J., Gröne E.F., Brandes R.P., Malle E., Olbricht C.J., Walli A.K., Gröne H.J. Oxidant stress in hyperlipidemia-induced renal damage. Am. J. Physiol. Renal Physiol. 278:2000;F63-74.
50. Gröne H.J., Gröne E.F., Malle E. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab. Invest. 82:2002;5-14.